Lara El Khalili, Linn El Khalili, Araz Rawshani, Jan Borén, Deepak L Bhatt, Hertzel C Gerstein, Darren K McGuire, Edvin Helleryd, Elmir Omerovic, Björn Eliasson, Truuls Råmunddal, Naveed Sattar, Aidin Rawshani
{"title":"Cardiometabolic risk factors and disease trends for atrial fibrillation in individuals with type 1 diabetes: a nationwide registry study.","authors":"Lara El Khalili, Linn El Khalili, Araz Rawshani, Jan Borén, Deepak L Bhatt, Hertzel C Gerstein, Darren K McGuire, Edvin Helleryd, Elmir Omerovic, Björn Eliasson, Truuls Råmunddal, Naveed Sattar, Aidin Rawshani","doi":"10.1186/s12933-024-02561-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To investigate standardized incidence of atrial fibrillation (AF) in individuals with type 1 diabetes (T1DMM) compared with matched controls from the general population. Additionally, to examine optimal levels- and relative importance of risk factors associated with AF and numbers of risk factors necessary to reduce excess risk in individuals with T1DM.</p><p><strong>Research design and methods: </strong>The study included individuals with T1DM between 2001 and 2019 and matched controls without T1DM. The outcome of interest was the first occurrence of AF. Standardized incidence rates and Cox regression were used for analyzing incidence and risk associations.</p><p><strong>Results: </strong>The study comprises analyses of data from 36,069 persons with T1DM and 165,705 matched controls; average age 34.1; 43.2% women. Incidence rates per 100,000 person years for AF in persons with T1DM declined between 2001 and 2019 from 671 to 494; also in controls from 568 to 317. However, results shows that those without cardiovascular disease at baseline, did not display a similar rate reduction over time. During this period, people with T1DM had a 1.34-fold (95% CI 1.24-1.46) higher adjusted hazard for incident AF than controls when adjusting for sociodemographic factors. This hazard was attenuated to 0.95 (95% CI 0.87-1.03) after also accounting for coronary, cerebrovascular, kidney disease and heart failure; among those with T1DM. In those, with several risk factors at baseline, we observed a hazard ratio from 1.61 (95%, 1.07-2.43), and there was also an indication of clear risk reduction in those with zero risk factors, albeit non-significant (HR 0.60, 95% CI 0.35-1.04). In the T1DM cohort, the first available value of hemoglobin A1c, systolic blood pressure, body mass index and estimated glomerular filtration rate were each independently associated with incident AF and we noticed a clear linear risk increase for several cardiometabolic risk factors.</p><p><strong>Conclusions: </strong>The crude incidence of AF was higher for persons with versus without T1DM, and declined significantly in both groups. Adjusting for data-derived predictors of AF attenuated higher risks, suggesting that the higher AF risk for persons with T1DM is driven by its common comorbidities.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"117"},"PeriodicalIF":8.5000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11905555/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Diabetology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12933-024-02561-z","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To investigate standardized incidence of atrial fibrillation (AF) in individuals with type 1 diabetes (T1DMM) compared with matched controls from the general population. Additionally, to examine optimal levels- and relative importance of risk factors associated with AF and numbers of risk factors necessary to reduce excess risk in individuals with T1DM.
Research design and methods: The study included individuals with T1DM between 2001 and 2019 and matched controls without T1DM. The outcome of interest was the first occurrence of AF. Standardized incidence rates and Cox regression were used for analyzing incidence and risk associations.
Results: The study comprises analyses of data from 36,069 persons with T1DM and 165,705 matched controls; average age 34.1; 43.2% women. Incidence rates per 100,000 person years for AF in persons with T1DM declined between 2001 and 2019 from 671 to 494; also in controls from 568 to 317. However, results shows that those without cardiovascular disease at baseline, did not display a similar rate reduction over time. During this period, people with T1DM had a 1.34-fold (95% CI 1.24-1.46) higher adjusted hazard for incident AF than controls when adjusting for sociodemographic factors. This hazard was attenuated to 0.95 (95% CI 0.87-1.03) after also accounting for coronary, cerebrovascular, kidney disease and heart failure; among those with T1DM. In those, with several risk factors at baseline, we observed a hazard ratio from 1.61 (95%, 1.07-2.43), and there was also an indication of clear risk reduction in those with zero risk factors, albeit non-significant (HR 0.60, 95% CI 0.35-1.04). In the T1DM cohort, the first available value of hemoglobin A1c, systolic blood pressure, body mass index and estimated glomerular filtration rate were each independently associated with incident AF and we noticed a clear linear risk increase for several cardiometabolic risk factors.
Conclusions: The crude incidence of AF was higher for persons with versus without T1DM, and declined significantly in both groups. Adjusting for data-derived predictors of AF attenuated higher risks, suggesting that the higher AF risk for persons with T1DM is driven by its common comorbidities.
期刊介绍:
Cardiovascular Diabetology is a journal that welcomes manuscripts exploring various aspects of the relationship between diabetes, cardiovascular health, and the metabolic syndrome. We invite submissions related to clinical studies, genetic investigations, experimental research, pharmacological studies, epidemiological analyses, and molecular biology research in this field.